ExThera Medical received funding from the Medical Technology Enterprise Consortium (MTEC) for a randomized controlled trial. The trial will evaluate the Seraph 100 blood filter’s effectiveness in treating sepsis from wound infections at LSU Health Shreveport. This research aims to improve outcomes for military personnel and civilians suffering from sepsis.
This trial is crucial because sepsis is a leading cause of death following combat trauma. A successful trial could provide a new tool for managing this deadly complication, significantly improving survival rates and long-term health outcomes for wounded soldiers. This also has broader implications for civilian healthcare, where sepsis remains a major concern. Effective treatment options are continually needed, especially given the rise of antibiotic-resistant infections.
The Seraph 100 is a unique device designed to remove a broad spectrum of pathogens from the bloodstream without adding anything to it. It has received multiple Breakthrough Device Designations from the FDA and has been used under Emergency Use Authorization for various severe infections. The MTEC trial, starting in December 2024, will involve 330 patients and anticipates its first patient enrollment in late Q2 2025. This collaboration between ExThera Medical and LSU Health Shreveport highlights the importance of public-private partnerships in advancing medical technology.
Positive trial results could lead to widespread adoption of the Seraph 100 by military medical facilities and civilian hospitals. This could transform sepsis treatment, offering a more effective and readily available option for managing this life-threatening condition. The trial’s outcome will be a critical step towards improving patient outcomes and potentially reducing the global burden of sepsis.
Source link: http://www.businesswire.com/news/home/20250122938794/en/ExThera-Medical-Receives-MTEC-Award-for-Pivotal-Sepsis-Trial
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
